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Abstract
Background: The MAD1 protein, a member of the MYC/MAX/MAD network of transcriptional regulators, controls
cell proliferation, differentiation and apoptosis. MAD1 functions as a transcriptional repressor, one direct target
gene being the tumor suppressor PTEN. Repression of this gene is critical to mediate the anti-apoptotic function of
MAD1. Under certain conditions it also antagonizes the functions of the oncoprotein MYC. Previous studies have
demonstrated that MAD1 expression is controlled by different cytokines and growth factors. Moreover we have
recently demonstrated that the MAD1 promoter is controlled by the cytokine granulocyte colony-stimulating factor
(G-CSF) through the activation of STAT3, MAP kinases and C/EBP transcription factors.
Results: We observed that in addition to G-CSF, the cytokine transforming growth factor b (TGFb1) rapidly induced
the expression of MAD1 mRNA and protein in promyelocytic tumor cells. Moreover we found that C/EBP and SP
transcription factors cooperated in regulating the expression of MAD1. This cooperativity was dependent on the
respective binding sites in the proximal promoter, with the CCAAT boxes being bound by C/EBPa/b heterodimers.
Both C/EBP and SP transcription factors bound constitutively to DNA without obvious changes in response to
TGFb1. In addition SMAD3 stimulated the MAD1 reporter, cooperated with C/EBPa and was bound to the core
promoter region. Thus SMAD3 appears to be a potential link between TGFb1 signaling and C/EBP regulated
promoter activity. Moreover TGFb1 stimulated the phosphorylation of polymerase II at serine 2 and its progression
into the gene body, consistent with enhanced processivity.
Conclusions: Our findings suggest that C/EBP and SP factors provide a platform of transcription factors near the
core promoter of the MAD1 gene that participate in mediating signal transduction events emanating from different
cytokine receptors. SMAD3, a target of TGFb1 signaling, appears to be functionally relevant. We suggest that a key
event induced by TGFb1 at the MAD1 promoter is the recruitment or activation of cofactors, possibly in complex
with C/EBP, SP, and SMAD3 transcriptional regulators, that control polymerase activity.
Background
The MYC/MAX/MAD network of transcriptional regu-
lators is essential to control many aspects of cell phy-
siology [1]. MYC was originally identified as oncogene
in several different chicken retroviruses. Subsequently
the three human MYC genes, MYC, MYCN and MYCL
were found deregulated in the large majority of human
tumors [2]. The potent capacity of MYC to transform
cells has also been supported by a large number of stu-
dies in both primary cells and established cell lines and
in animal models. Central to the ability to transform
cells is MYC’s function as transcriptional regulator in
controlling the expression of a large number of target
genes. This explains, at least in part, the broad biological
activities associated of MYC [3,4]. The functions of
MYC in gene expression control depend largely on its
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MYC/MAX/MAD network.
MAD proteins are alternative binding partners of
MAX [5]. Six different MAD proteins have been identi-
fied. MAD1-4 are highly related, while MNT and MGA
are considerably larger multi-domain proteins. Similar
to MYC, the MAD proteins are transcriptional regula-
tors, with MAD1-4 primarily described as repressors.
Unlike MYC proteins, the MADs have not been linked
to human diseases, in particular they appear not to be
tumor suppressors as one might have expected. For
MAD1-4 the reason for their apparent lack to function
as tumor suppressors may be in part due to their broad
and overlapping expression pattern, suggesting that
more than one MAD family member would need to be
inactivated in tumors [5]. In addition, MAD proteins,
best studied for MAD1, have anti-apoptotic activity and
thus may antagonize the pro-apoptotic functions of
MYC proteins [6-8]. This activity of MAD proteins may
be indispensable for tumor development. In support,
one of the few MAD1 target genes that has been identi-
fied is the tumor suppressor gene PTEN [8]. MAD1,
which functions primarily as a transcriptional repressor
by recruiting histone deacetylase-containing complexes
[9-12], represses the PTEN promoter directly [8]. This
contributes to the anti-apoptotic phenotype elicited by
MAD1. The analysis of granulocytes from mice lacking
Mad1 revealed increased sensitivity to pro-apoptotic
conditions [6], further supporting the view that MAD1
protects cells from different apoptotic stimuli.
In addition to the anti-apoptotic function, MAD1 has
been suggested to control proliferation and differentia-
tion antagonistically to MYC [5]. Indeed the unsched-
uled expression of MAD1 interferes with cell
proliferation and the lack of Mad1 results in a differen-
tiation defect of granulocytes [6,7,13-15]. During the
studies to elucidate the functions of MAD1 in prolifera-
tion and differentiation, it had been noted early on that
the expression of the MAD1 gene is highly regulated,
generally reciprocal to the regulation of MYC genes [5].
Moreover MAD1 expression is directly downregulated
by MYC (NH and BL, unpublished observations). In
particular several differentiation inducing agents, includ-
ing transforming growth factor b (TGFb), retinoic acid,
and granulocyte-colony stimulating factor (G-CSF), were
identified as stimulators of MAD1 expression [16-20].
These findings led us to address the question how the
MAD1 promoter is organized and how signals of these
differentiation factors control gene expression. The
MAD1 promoter contains a CpG island as part of a
roughly 400 bp proximal promoter region highly con-
served between humans and rodents [17]. This region is
responsive to G-CSF, integrating signals transduced
from the G-CSF receptor by STAT3 and by the RAS-
RAF-ERK pathway. This regulation of the MAD1 pro-
moter by G-CSF is in agreement with the described role
of this cytokine and of Mad1 in the control of granulo-
cyte differentiation and survival [6].
Cytokines of the TGFb family have broad activities in
controlling cell physiology, including proliferation, dif-
ferentiation and survival [21-23]. TGFb signals through
TGFb type II and I receptors with Ser/Thr kinase activ-
ity, thereby activating SMAD proteins, in particular
SMAD2 and 3 in combination with SMAD4. These pro-
teins translocate to the cell nucleus and form complexes
with additional molecules to control the expression of
target genes [24]. We have shown previously that the
phorbol ester TPA and TGFb activate the expression of
MAD1 in U937 and in HaCaT keratinocytes, respec-
tively [18,19]. In both systems a substantial increase in
mRNA expression was observed by 90 min, suggesting
that the induction was direct. Different kinetics of
MAD1 induction were observed in a clone of U937 pro-
myelocytes that stably express a viral version of MYC
(U937-myc6). In these cells a weak induction was
observed in response to TGFb by 8 hrs, possibly as a
result of constitutive MYC expression [20]. To under-
stand in more detail how TGFb1 regulates MAD1 gene
expression, we addressed how this cytokine affects
MAD1 promoter activity. It appears that TGFb1 stimu-
lates MAD1 through elements proximal to the core
promoter.
Results and Discussion
Rapid activation of MAD1 by TGFb
During cell proliferation and differentiation, the MAD1
gene is regulated by multiple signaling pathways. One of
the regulatory cytokines is TGFb1, which is known to
induce MAD1 in keratinocytes and in U937-myc6 pro-
myelocytes [19,20]. To further evaluate the role of
TGFb1 in regulating MAD1, we performed time course
experiments. TGFb1 rapidly activated MAD1 mRNA
expression in U937 cells (Figure 1A). In parallel, MAD1
protein became detectable within 4 hrs of TGFb1 stimu-
lation (Figure 1B). Thus the induction of MAD1 protein
follows closely the up-regulation seen at the mRNA
level. The induction of MAD1 expression was dependent
on the TGFb receptor (TGFbR) since the TGFbRI inhi-
bitor SB505124 blocked MAD1 activation (Figure 1C).
Moreover inhibition of the MAPK p38 resulted in a par-
tial inhibition of MAD1 expression in response to
TGFb1, whereas the inhibition of JNK or ERK kinases
did not repress MAD1 expression (Figure 1C). The
activities of the inhibitors were verified by analyzing the
phosphorylation of the relevant kinases (data not
shown). These findings indicate that TGFb1 may signal
by different pathways to the MAD1 promoter. Indeed
the TGFbR is known to activate several different
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factors, including different MAP kinases and the PI3K-
AKT pathway [25].
MAD1 has been demonstrated to interfere with cell
proliferation in some cell types [7,14]. Therefore we
measured whether the induction of MAD1 by TGFb1
affected the proliferation of U937 tumor cells. However
the early TGFb1-stimulated induction of MAD1 was not
sufficient to block U937 proliferation (Figure 1D), simi-
lar to the observations made in U937-myc6 cells [20].
Our findings suggest that tumor cells like U937 have
the possibility to bypass at least transiently the repres-
sive function of MAD1 in cell proliferation.
C/EBPa/b heterodimers bind constitutively to the MAD1
promoter
The MAD1 promoter does not contain any obvious
SMAD binding sites in the proximal region. Indeed a
recent study suggested that SMAD2/3 stimulate MAD1
expression independent of SMAD4, possibly through an
indirect mechansism [26]. Moreover it has been found
that SMAD proteins may interact with C/EBP transcrip-
tion factors to control gene expression [27]. Since we have
shown previously that C/EBPs control the transcription of
MAD1 in response to the cytokine G-CSF in RK13 rabbit
epithelial cells [17], we addressed the role of C/EBP
transcription factors in human cells. Transient transfection
experiments in HeLa cells demonstrated that C/EBPa and
b, and to a lesser extend C/EBPε, were able to stimulate
-1282 to +248 and -184 to +248 (relative to the major
transcriptional start site) MAD1 promoter reporter gene
constructs (Figure 2A-C). Moreover knockdown of C/
EBPb reduced MAD1 promoter reporter gene activity,
suggesting that its expression is controlled by endogenous
C/EBPb (Figure 2D and 2E). This appears to be a direct
effect since the mutation of the two CCAAT box-like
sequences in the promoter proximal region affected the
sensitivity to C/EBPb (Figure 2A). Deletion of box1
reduced, while deletion of either box2 or both elements
together eliminated promoter activity in response to C/
EBPb (Figure 2F). Together these findings demonstrate
that, similar to the observations in RK13 cells, C/EBPs also
control MAD1 expression in human cells.
To address whether TGFb1 might affect C/EBP bind-
ing to the MAD1 promoter, ChIP experiments were per-
formed. Specific C/EBPb binding to the core-promoter
region was observed, whereas only weak interaction
with a more distal promoter region could be detected
(Figure 3A). C/EBPb was found at the MAD1 promoter
prior to TGFb1 signaling (Figure 3A). Stimulation by
TGFb1 did not result in altered binding. Thus C/EBP
proteins interact with the promoter independent of
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Figure 1 Induction of MAD1 mRNA and protein expression in response to TGFb1i nU 9 3 7c e l l s . A. Exponentially proliferating U937
promyelocytes were treated with 2.5 ng/ml of TGFb1. mRNA was purified at the indicated time points. The kinetics of MAD1 expression in
response to TGFb1 were analyzed by quantitative RT-PCR. The mean values ± SD of three independent experiments are shown. B. Whole cell
extracts of U937 cells treated as in panel A were generated at the indicated time points and analyzed for endogenous MAD1 protein by western
blotting. Tubulin served as loading control. C. U937 cells were pre-treated with the TGFb receptor I inhibitor SB505124 (5 μM) for 40 min prior to
addition of TGFb1. MAD1 expression was assayed by quantitative RT-PCR 2 hrs after TGFb1 stimulation. The displayed data are mean values ± SD
of three independently performed experiments. D. U937 cells were initially diluted to a density of 10
5 cells/ml and incubated with 2.5 ng/ml
TGFb1 over a period of 48 hrs. The number of cells was determined at the indicated time-points by CASY measurements.
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Figure 2 MAD1 promoter reporter gene constructs are regulated by C/EBP transcription factors. A. Schematic representation of the
position of the CCAAT box (half-sites) and GC box motifs within the MAD1 promoter region. The major transcriptional start site is indicated with
+1. B. and C. HeLa cells were co-transfected with the -1284 to +248 or the -184 to +248 reporter gene constructs, respectively, and plasmids
encoding the three indicated C/EBP proteins. The promoter-less pGL2 construct served as negative control and its activity was set as 1. The
luciferase measurements were normalized to b-galactosidase activities expressed from a co-transfected plasmid. D. Reporter gene assays were
performed in HeLa cells by co-transfecting the -184 to +248 reporter gene construct and a pSuper-based shRNA targeting C/EBPb or a control
shRNA. Luciferase activity was determined 2 days after transfection. E. The efficiency of the shRNA targeting C/EBPb was examined in HeLa cells
by immunoblotting. C/EBPb-specific antibodies were used to detect the two major isoforms of endogenous C/EBPb proteins, LAP and LIP, in
whole cell extracts. F. The C/EBPb-mediated relative activation of the indicated MAD1 promoter constructs were analyzed in reporter gene assays
performed in HeLa cells as described above.
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Figure 3 C/EBPb binds to the chromatin embedded MAD1 promoter in cells. A. Schematic presentation of the MAD1 promoter relative to
the major transcriptional start site with the homology region as defined in [17]. The positions of primer sets used for ChIP PCR are given (upper
panel). U937 cells were used in ChIP assays to investigate the binding of C/EBPb to the MAD1 promoter in response to TGFb1. The cells were
treated with 2.5 ng/ml TGFb1 for 1.5 hrs prior to crosslinking and immunoprecipitation, and the purified DNA was analyzed by PCR with the
indicated primers. The displayed experiment is representative of three independent experiments with similar outcome. B. C/EBPb was expressed
in HEK293 cells. Whole cell extracts were generated and incubated with [
32P]-radiolabelled CCAAT box1 oligonucleotids derived from the MAD1
or the neutrophil elastase promoter (NE-CCAAT). Supershift experiments with C/EBPb specific antibodies are indicated. The complexes were
analyzed by EMSA and detected by autoradiography. Ø, indicates lanes without cell extracts; +, whole cell extracts of control transfected HEK293
cells; b, whole cell extracts of HEK293 cells transiently expressing C/EBPb. C. The C/EBPa/b heterodimer DNA-binding activity to CCAAT box1 was
determined by EMSA. HEK293 cell extracts overexpressing C/EBPa and C/EBPb were generated as in panel B and incubated with radiolabelled
CCAAT box1. Supershift experiments were performed with C/EBPa- or C/EBPb-specific antibody. For control an irrelevant oligonucleotide was
used. D. Re-ChIP experiment using C/EBPa- and C/EBPb-specific antibodies in U937 cells treated with or without TGFb1 for 1.5 hrs. The first
immunoprecipitation was performed with antibodies specific for C/EBPb. The protein-DNA complexes were then released and subjected to a
second immunoprecipitation using C/EBPa or C/EBPb specific antibodies. The isolated DNA was analyzed by quantitative PCR with the primer
set P (panel A) amplifying a portion of the homology region of the MAD1 promoter. The signal intensities obtained with the specific
immunoprecipitations were normalized to samples generated with control antibodies. For all panels one representative of typically at least three
independent experiments are shown.
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CCAAT box motifs, both appear only to be half-sites
[17], was further evaluated using electrophoretic mobi-
lity shift assays (EMSA). Neither of the two half-sites
(i. e. CCAAT box1 and CCAAT box2) was bound by C/
EBPa or C/EBPb homodimers alone when expressed in
HEK293 cells (Figure 3B and data not shown). For con-
trol efficient and specific binding of C/EBPb and C/
EBPa to a CCAAT box of the neutrophil elastase gene
was measurable, as reported previously [28] (Figure 3B
and data not shown). Since the findings using ChIP and
EMSA were contradictory, we expanded the EMSA
experiments by evaluating the binding of C/EBPa/b het-
erodimers. In contrast to the homodimers, the heterodi-
meric C/EBP complexes interacted with the CCAAT
box1 (Figure 3C) and less well with CCAAT box2 (data
not shown). The presence of a heterodimeric complex
at CCAAT box1 was verified using C/EBPa and b speci-
fic antibodies. Both antibodies were able to supershift
the complexes observed, further validating that C/EBPa/
b h e t e r o d i m e r sw e r ea b l et ob i n dt ot h eMAD1 promo-
ter. To address whether the chromatin embedded
MAD1 promoter was bound by C/EBPa/b heterodimers,
re-ChIP experiments were performed by immunopreci-
pitating first chromatin-bound C/EBPb. The bound
material was released and re-immunoprecipitated with
antibodies specific for either C/EBPa or C/EBPb (sec-
ond immunoprecipitation) in comparison to a control
(Figure 3D). The specific signals obtained with both C/
EBP antibodies suggested that indeed the MAD1 promo-
ter was occupied by C/EBPa/b heterodimers. Again this
was largely independent of TGFb signaling (Figure 3D).
SP transcription factors bind to the MAD1 promoter
independent of TGFb signaling
In addition to CCAAT boxes, the proximal promoter
region of the MAD1 gene contains 2 prominent GC
boxes (Figure 2A). To test whether SP proteins can bind
to either of these two GC boxes, we performed EMSA
and ChIP experiments. Prominent binding to an oligo-
nucleotide spanning GC box1, which is flanked by the
two CCAAT boxes, was observed in EMSA experiments
using U937 cell extracts (Figure 4A). Binding to GC
box2 was weaker (data not shown). Supershift experi-
ments using specific antisera indicated that both SP1
and SP3 proteins bind to GC box1 (Figure 4A). More-
over both proteins bound constitutively to the chroma-
tin embedded proximal MAD1 promoter that contains
GC box1 and no change in response to TGFb1w a s
measurable (Figure 4B and data not shown). Similarly
the binding of SP1 and SP3 to the MAD1 promoter was
not affected by G-CSF (data not shown), indicating that
these transcription factors as well as C/EBP proteins are
constitutively interacting with the MAD1 promoter.
C/EBP and SP transcription factors cooperate in
stimulating the MAD1 promoter
Since the CCAAT and GC boxes are in close proximity
within the MAD1 promoter (Figure 2A), we addressed
whether SP1 and C/EBPb were able to cooperate on
MAD1 reporter gene constructs. While SP1 alone had
no effect on the expression of the reporter gene, it
substantially stimulated C/EBPb-dependent expression
(Figure 5A). This observation was further validated by
expressing a dominant negative form of SP1 (SP1dn),
which lacks the transactivation domain. SP1dn repressed
efficiently C/EBPb-induced MAD1 promoter reporter
gene expression (Figure 5B). The cooperative effect of
SP1 and C/EBPb was dependent on the GC and
CCAAT boxes (Figure 5C and 5D). Together these find-
ings suggest that SP and C/EBP proteins bind to the
proximal MAD1 promoter and cooperate in activating
the MAD1 promoter.
SMAD3 interacts with and activates the MAD1 promoter
dependent on C/EBP and SP binding sites
Next we evaluated whether SMAD proteins are involved
in activating the MAD1 promoter by using the -1282 to
+248 MAD1 promoter reporter gene construct. This
reporter was stimulated by a combination of SMAD2, 3,
and 4 but the activity of these factors was not enhanced
by coexpressing a constitutive active TGFbRI (TGFbRca)
(Figure 6A). All these constructs however were active
since a SMAD binding element reporter (SBE-luc) was
s t r o n g l ya c t i v a t e db yS M A D sa n dT G F bRca (Figure 6B
and 6C). In the absence of exogenous SMAD proteins
the TGFbRca was unable to significantly activate MAD1
promoter reporter constructs (Figure 6D). We further
evaluated which SMAD protein(s) stimulated the MAD1
promoter reporter. We found by testing all combina-
tions that only SMAD3 was stimulatory (data not
shown). The SMAD3 responsive region was mapped to
the promoter fragment that contains the two C/EBP half
sites and one SP binding site, i.e. GC box1 (Figure 6E,
for the positions of the binding sites see Figure 2A).
These response elements appeared to be relevant
because mutation of these sites in a reporter containing
the -184 to -58 MAD1 promoter fragment upstream of
the minimal thymidine kinase promoter (minTK)
resulted in almost complete loss of SMAD3 responsive-
ness (Figure 6F). Consistent with this, C/EBPa and
SMAD3 cooperated on the -184 MAD1 promoter repor-
ter (Figure 6G). Finally we addressed whether SMAD3
interacted with the MAD1 promoter. Indeed we found
that SMAD3 was bound to the MAD1 promoter but not
to an irrelevant promoter (MYOD1)( F i g u r e6 F ) .H o w -
ever stimulation of the U937 cells with TGFb did not
alter significantly the interaction of SMAD3 with the
promoter. Together these findings demonstrate that
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for the MAD1 promoter. The lack of regulation by coex-
pressing SMAD3 with TGFbRca as measured by repor-
ter gene assays may be due to insufficient chromatin
formation on the transfected DNA and/or additional
important signaling compounds are missing.
TGFb1 stimulates Ser2 phosphorylation of Pol II
To further evaluate how the MAD1 promoter is acti-
vated, we analyzed acetylation of histone H3 (H3ac) and
trimethylation at Lys 4 of histone H3 (H3K4me3) before
and after TGFb1 stimulation. Both are marks for active
promoters. We observed H3ac throughout the locus and
H3K4me3 at the promoter, however, none of these
marks was significantly modified by TGFb1 stimulation
(Figure 7A-C). These findings suggest that the MAD1
promoter is in an open configuration, similar to what
has been observed recently for many promoters of regu-
lated genes [29-31]. This is supported by our previous
studies using nucleosomal mapping demonstrating open
chromatin at the MAD1 proximal promoter [17]. Con-
sistent with an open configuration is our observation
that polymerase II (Pol II) occupied the MAD1 promo-
ter constitutively (Figure 7D). Pol II was also detected in
the gene body, where its binding increased in response
to TGFb1 treatment (Figure 7D). A key step in activat-
ing transcription is the differential phosphorylation of
Pol II [32,33]. It is phosphorylated at Ser-5 of its C-
terminal domain (CTD), a modification that defines a
preactivation state. Upon stimulation, Pol II becomes
phosphorylated at Ser-2 of the CTD, which coincides
with elongating polymerase. Therefore we addressed
whether phosphorylation at Ser-5 and Ser-2 was altered
in response to TGFb1. Indeed we observed an increase
in Ser-2 phosphorylation upon TGFb1 stimulation and a
concomitant decrease of Ser-5 phosphorylation of Pol II
both at the promoter and in the gene body (Figure 7D).
Thus TGFb1 regulates Pol II phosphorylation and
activity.
Conclusions
We observed that C/EBP and SP transcription factors
bind constitutively to the proximal MAD1 promoter. In
addition SMAD3, a factor typically activated by TGFb
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Page 8 of 13signaling, also was found constitutively on the MAD1
promoter, despite the fact that no obvious binding sites
for SMAD proteins are found. While the GC boxes are
consensus binding sites for SP1, the proposed CCAAT
boxes are deviating considerably from C/EBP consensus
sequences. In fact, both elements that were identified
functionally, represent only half sites [17]. Consistent
with this interpretation, these DNA elements do not
bind efficiently C/EBP homodimers in EMSA experi-
ments in vitro. Surprisingly substantial binding was only
measurable with C/EBPa/b heterodimers in these
EMSA experiments. Nevertheless both factors were able
to stimulate MAD1 promoter reporter genes. We did
however not observe a strong synergistic activation by
the two proteins, possibly due to abundant endogenous
C/EBP factors (data not shown). We suggest that C/EBP
and SP transcription factors form a platform for incom-
ing signals as exemplified by G-CSF [17] and possibly
TGFb1. In the case of G-CSF, STAT3 is recruited by C/
EBPs, requiring MAPK signaling. Our new findings
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Figure 6 Influence of SMAD proteins and TGFb1 receptor signaling on MAD1 promoter activity. A. HeLa cells were co-transfected with
the -1282 to +248 reporter gene construct and SMADs and/or TGFbRca or TGFbR expression vectors as indicated. For control the pGL2 reporter
was measured. B and C. As in A except that the SMAD binding element (SBE) reporter gene was used. D. The effect of TGFbRca and TGFbR was
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interact with C/EBP proteins and ΔGC-box to the mutation of the SP binding site as described preciously [17]. G. HeLa cells were co-transfected
with the -184 to +248 reporter gene construct and C/EBPa and SMAD3 as indicated. For control the pGL2 reporter was measured. H. U937 cells
were treated for the indicated times with TGFb1. The cells were then fixed in formaldehyde, lysed and the DNA fragmented. The binding of
SMAD3 to the MAD1 promoter was measured after specific immunoprecipiation and analysis of the promoter region using the primers given in
figure 4B (P and P’). For control an irrelevant promoter, MYOD1, was used. The binding is given as % of input control.
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Page 9 of 13suggest that TGFb1 signaling activates SMAD proteins
and stimulates MAPK signaling. The activation of
MAPK might be a common pathway that controls at
least in part MAD1 expression. Consistent with this
interpretation, SMAD3 cooperated with C/EBP proteins
to activate MAD1 promoter reporter genes. The finding
that SMAD3 was bound to the MAD1 promoter sug-
gests that SMAD3 is directly recruited to the MAD1
promoter by binding to C/EBPs or C/EBP associated
factors. Because the GC box was also relevant, we pro-
pose that a large transcription factor/cofactor complex
interacts with the identified promoter proximal region,
including SMAD3. However, we point out that we can-
not exclude direct binding of SMAD3 to the MAD1 pro-
moter. Although no obvious binding sites could be
detected, SMAD binding sites are rather short and leave
the possibility open that SMAD3 forms a dimeric or
multimeric complex with other factors, in which
SMAD3 might bind directly to DNA.
The signals that are integrated at the proximal MAD1
promoter translate into the activation of Pol II as mea-
sured by its progression into the gene body and the con-
comitant change in the phosphorylation of the
C-terminal domain of Pol II. This is consistent with
recent observations on many genes, which have pro-
vided evidence that Pol II phosphorylated at Ser-5 is
located at the promoter in a preactivated or paused
mode. The switch to Ser-2 phosphorylation, possibly by
the recruitment and activation of the P-TEFb kinase
CDK9, results in the activation and promoter clearance
of Pol II [34]. Thus this represents a situation as it is
now becoming evident at many different promoters that
are being studied in detail. It is worth noting that Pol II
was found to be associated with the MAD1 promoter
prior to stimulation with cytokines. Thus at least in
U937 tumor cells, the MAD1 promoter is preoccupied
by Pol II and thus allows for rapid activation by multiple
signals. It will now be of interest to specifically dissect
how different cytokines use the C/EBP-SP transcription
factor platform to activate the paused Pol II.
Methods
Reporter gene construct and expression vectors
The cloning of MAD1 promoter reporter gene con-
structs has been reported previously [17]. Descriptions
of pEQ176-ß-galactosidase, pCB6
+-C/EBPa, and pCB6
+-
C/EBPb are found in [28,35]; pCDNA3+-C/EBPε was
obtained from A. Friedman [36]; pCL-neo-HA-SP1 and
pCI-neo-HA-SP1-N (a dominant negative form of SP1)
were provided by H. Rotheneder [37].
Cell culture and treatment
HEK293 (ATCC CRL-1573) and HeLa (ATCC CCL-2)
cells were cultured in DMEM (Gibco) with 10% fetal
calf serum (Gibco) and penicillin/streptomycin (Ser-
omed). U937 (ATCC CRL-1593.2) promyelocytes were
grown in RPMI 1640 (Gibco) with 10% fetal calf serum
and penicillin/streptomycin. All cells were cultured at
37°C and 5% CO2. U937 cells were treated with TGFb1
(Peprotec) at a concentration of 2.5 ng/ml and with
5 μM SB505124 (Sigma-Aldrich) as indicated. Prolifera-
tion and viability of U937 cells were analyzed using Try-
pan Blue staining and the CASY cell counting system
(Innovatis).
Transient transfection and luciferase assay
Transient transfection of HEK293 and HeLa cells were
performed using the calcium phosphate co-precipitation
method as described previously [38]. HeLa cell co-
transfected with pSuper-sh-C/EBPb were harvested 72
hours post-transfection. For luciferase assays HeLa cells
were co-transfected overnight with a total amount of 3-
5 μg plasmid DNA and cultured for 48 hrs under
A
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Figure 7 Histone modifications and Pol II loading at the MAD1
promoter. A. Summary of primer sets used for ChIP PCR relative to
the major transcriptional start site within the MAD1 gene. B. and C.
Proliferating U937 cells were treated with or without 2.5 ng/ml
TGFb1 for 1.5 h. ChIP experiments were performed with the
indicated antibodies and primers. For control the
immunoprecipitations were performed with Protein A Sepharose
beads only. Signals obtained from input DNA, given as part of the
immunoprecipitated material, are shown for comparison. D. U937
cells were treated with or without 2.5 ng/ml TGFb1 for 20 and 40
min prior to cross-linking. For ChIP, total Pol II and Ser-2 and Ser-5
phosphorylated Pol II was immunoprecipitated. Loading and
distribution of the different Pol II isoforms were examined on the
MAD1 gene with the indicated primers.
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Page 10 of 13normal growth conditions prior to harvesting. Luciferase
activity was measured using a bioluminator (ELISA-
Reader Victor2). The relative luciferase activity was nor-
malized to the b-galactosidase activity. All experiments
were performed in duplicates or triplicates with at least
three independent replicates.
The online program siDirect (genomics.jp/sidirect)
was used to design shRNA oligonucleotides targeting
the C/EBPb mRNA and the resulting sequences were
analyzed via the BLAST algorithm. The hybridized oli-
gonucleotides were cloned into the pSuper vector
(obtained from R. Bernards) linearised with BglII and
HindIII [39].
Sense: 5’GATCCCCAGCACAGCGACGAGTACAA-
TCTTCAAGAGAGATTGTACTCGTCGCTGTGCTTT
TTTGGAAA;
Antisense: 5’AGCTTTTCCAAAAAAGCACAGCGAC-
GAGTACAATCTCTCTTGAAGATT
GTACTCGTCGCTGTGCTGGG.
RNA preparation and quantitative RT-PCR
The RNAeasy Mini Kit (Qiagen) was used for total RNA
extraction, according to the manufacturer’s instruction
and residual genomic DNA was removed by DNase
(Qiagen) digestion. 1 μg total RNA was reverse tran-
scribed into cDNA using the Transcriptor First Strand
cDNA Synthesis Kit (Roche) and analyzed by quantita-
tive real time PCR using a LightCycler (Roche). The real
time PCR reactions were performed with the SYBRgreen
Ready Mix (Qiagen) and the following primer pairs:
MAD1 QantiTect primer assay (Qiagen) and b-GLU-
CURONIDASE-f 5’-CTCATTTGGAATTTTGCCGATT-
3’, b-GLUCURONIDASE-r 5’-CCGAGTGAAGATCC
CCTTTTTA-3’. The relative quantification of MAD1
mRNA was calculated by the comparative CT method
and normalized to b-GLUCURONIDASE using the Soft-
ware RelQuant.
Chromatin immunoprecipitation (ChIP) assay and RE-ChIP
assay
ChIP assays were performed as described previously [9].
U937 cells were grown in a spinner flask to a maximal
density of 10
6 cells/ml. Following TGFb1 treatment 5-
2.5 × 10
7 cells/ml per IP were harvested. For immuno-
precipitation 2 μg of the following antibodies were used:
H3ac (06-599, Upstate); H3K4me3 (8580-50, Abcam);
Pol II N20 (SC-899, Santa Cruz Biotechnology); Pol II
CTD phosphoserine 2 H5 (MMS-129R, Covance); Pol II
CTD phosphoserine 5 H14 (MMS-134R, Covance), C/
EBPa 14AA (SC-61, Santa Cruz Biotechnology); C/EBPb
C19 (SC-150, Santa Cruz Biotechnology), SP1 PEP2
(SC-59, Santa Cruz Biotechnology), SP1 (07-124,
Upstate), Cytochrome C (SC-7159, Santa Cruz Biotech-
nology), SMAD3 (ab28379 Abcam). In addition SP1-
specific antibodies were obtained from G. Suske [40].
The following primer pairs were used for PCR analysis
of the MAD1 gene:
U: 5’CCTCTTAATATACTGTCCTATGC-3’;
U’:5 ’GTCACAGCTCTCCAGAAATAGAAG-3’;
P: 5’AGTTGCGAATCCTGTCACCA-3’;
P’:5 ’TTCTCTTGACAGGCCAGCTT-3’;
G: 5’-ATATTGTAGGTGACACAAACTGC-3’;
G’:5 ’-ATCTCACTTGAAGCTTCCACAG-3’
MYOD1: 5’-CCGCCGCTTTCCTTAACCACAAAT-3’
MYOD1’:5 ’-GTAGATAGCAAAGTGCTGGCAGTC-3’
For Re-ChIP assays the first immunoprecipitation was
performed as above. Then the samples were washed
once in ChIP RIPA buffer (150 mM NaCl, 10 mM Tris-
HCl pH 7.5, 1 mM EDTA, 1% NP40, 0.1% DOC, 0.1%
SDS, 0.5% aprotinin) and the protein-DNA complexes
solubilized in release buffer (1% SDS, 10 mM DTT, TE-
buffer pH 7.5). The beads were incubated at 37°C for
30 min. To the supernatant 4 volumes of RIPA-SDS
(150 mM NaCl, 10 mM Tris pH 7.5, 1% NP40, 1% DOC,
0.5% aprotinin, 1 mM EDTA, 1 mM iodoacetamid) were
added to perform the second immunoprecipitation.
Electrophoretic mobility shift assay (EMSA)
The following oligonucleotides were g
32P-ATP radiola-
bleled and used in EMSAs:
CCAAT-b1 f: 5’AGCCCTCTCCCAATCGCACAAG3’;
CCAAT-b1 r: 5’CTTGTGCGATTGGGAGAGGGCT-3’;
NE-CCAAT f: 5’-TCGAGATGGGGCAATAT-3’;
NE-CCAAT r: 5’-ATATTGCCCCATCTCGA-3’;
GC box1 f: 5’-AAGTGTAGGGGCGGGGCATTCT-3’;
GC box1 r: 5’-AGAATGCCCCGCCCCTACACTT-3’.
HEK293 whole cell extracts were prepared on ice in
Frackelton-lysis buffer (10 mM Tris-HCL pH 7.05, 50
m MN a C l ,3 0m MN a 4 P 2 O 7 ,5 0m MN a F ,5μM
ZnCl2, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 100
μMN a 3 V O 4 ,1 5 0μM benzamidin, 0.025 U/ml
a-macroglobulin, 2.5 μg/ml leupeptin, 14 μg/ml aproti-
nin). Whole cell extracts were incubated with the radi-
olabeled oligonucleotides at 30°C for 30 min and then
subjected to electrophoresis as described previously [41].
In brief, for supershift assays antibodies or equivalent
amounts of control antibodies or BSA were added and
incubated on ice for 10 min, prior to oligonucleotide
addition. The protein-DNA complexes were separated
on a 4.5% polyacrylamide gel containing 7.5% glycerol in
0.25-fold TBE (20 mM Tris base, 20 mM boric acid, 0.5
m ME D T A ,p H8 )a t2 0V / c mf o r4h .G e l sw e r ef i x e d
in 10% methanol, 10% acetic acid, and 80% water for 1
h, dried, and autoradiographed. The following antibodies
were used in EMSAs: C/EBPa 14AA (SC-61, Santa Cruz
Biotechnology); C/EBPb C19 (SC-150, Santa Cruz Bio-
technology); SP1 PEP2 (SC-59, Santa Cruz Biotechnol-
ogy), SP1 (07-124, Upstate), SP3 D-20 (SC-644, Santa
Hein et al. BMC Molecular Biology 2011, 12:9
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Cruz Biotechnology).
Western blotting
To generate highly concentrated U937 whole cell extracts
(10
7 cells/preparation), U937 cells were lysed in 20 - 30 μl
FT Lysis buffer (600 mM KCL, 20 mM Tris-Cl pH 7.8,
20% glycerol, 10 μg/ml leupeptin, 10 μg/ml pepstatin A,
14 μg/ml, aprotinin, 0.4 mg/ml, Pefabloc) by pipeting up
and down as described previously [42]. The freeze-thaw
cycles in liquid nitrogen were repeated five times. The
thawed lysates were incubated with 250 U Benzonase
(Merck) at RT for 10 min. Whole cell extracts were
resolved by SDS-Page and transferred onto nitrocellulose
membranes, probed with MAD1 C19 (SC-222, Santa Cruz
Biotechnology), a-Tubulin (B-5-1-2, T-5168, Sigma), or
C/EBPb C19 (SC-150, Santa Cruz Biotechnology) antibo-
dies followed by horseradish peroxidase (HRP)-labeled
secondary antibody. Detection was performed with the
either chemiluminescence ECL kit (Pierce) or SuperSignal
West Femto Maximum Sensitivity Substrate (Pierce).
List of abbreviations
C/EBP: CCAAT-enhancer-binding protein; ChIP: Chromatin
immunoprecipitation; CTD: Carboxy-terminal domain; DMSO: Dimethyl
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